A phase II trial of lenalidomide, dexamethasone and cyclophosphamide for newly diagnosed patients with systemic immunoglobulin light chain amyloidosis

British Journal of Haematology

Volumn 170, Issue 6, 2015, Pages 804-813

  Cibeira, Maria T ^a   Oriol, Albert ^b   Lahuerta, Juan J ^c   Mateos, Maria Victoria ^d   de la Rubia, Javier ^e   Hernández, Miguel T ^f   Granell, Miquel ^g   Fernández de Larrea, Carlos ^a   San Miguel, Jesús F ^h   Bladé, Joan ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^c HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^d Centro de Investigacion del Cancer   (Spain)

^e HOSPITAL UNIVERSITARIO LA FE   (Spain)

^f HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

^g HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^h UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

AL amyloidosis; Cyclophosphamide; Dexamethasone; Lenalidomide; Untreated

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOPHOSPHAMIDE; DEXAMETHASONE; IMMUNOGLOBULIN LIGHT CHAIN; LENALIDOMIDE; ANTINEOPLASTIC AGENT; THALIDOMIDE;

ADULT; AGED; AMYLOIDOSIS; ARTICLE; BLOOD TOXICITY; CAUSE OF DEATH; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE ASSOCIATION; DISEASE COURSE; DIZZINESS; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEART ARRHYTHMIA; HEART DISEASE; HUMAN; IMMUNOGLOBULIN LIGHT CHAIN AMYLOIDOSIS; INFECTION; KIDNEY FAILURE; LUNG EMBOLISM; MALE; MIDDLE AGED; MOOD DISORDER; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYOPATHY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RASH; RESPIRATORY DISTRESS; SURVIVAL RATE; SYNDROME DELINEATION; THROMBOSIS PREVENTION; TREMOR; VERY ELDERLY; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; METABOLISM; MORTALITY; SURVIVAL; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; AMYLOIDOSIS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; MALE; MIDDLE AGED; SURVIVAL ANALYSIS; THALIDOMIDE; TREATMENT OUTCOME;

EID: 84940607866     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.13500     Document Type: Article

References (34)

1. Cibeira, M.T., Sanchorawala, V., Seldin, D.C., Quillen, K., Berk, J.L., Dember, L.M., Segal, A., Ruberg, F., Meier-Ewert, H., Andrea, N.T., Sloan, J.M., Finn, K.T., Doros, G., Blade, J. & Skinner, M. (2011) Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients. Blood, 118, 4346-4352.
2. Comenzo, R.L., Reece, D., Palladini, G., Seldin, D., Sanchorawala, V., Landau, H., Falk, R., Wells, K., Solomon, A., Wechalekar, A., Zonder, J., Dispenzieri, A., Gertz, M., Streicher, H., Skinner, M., Kyle, R.A. & Merlini, G. (2012) Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis. Leukemia, 26, 2317-2325.
3. Dinner, S., Witteles, W., Afghahi, A., Witteles, R., Arai, S., Lafayette, R., Schrier, S.L. & Liedtke, M. (2013) Lenalidomide, melphalan and dexamethasone in a population of patients with immunoglobulin light chain amyloidosis with high rates of advanced cardiac involvement. Haematologica, 98, 1593-1599.
4. Dispenzieri, A., Gertz, M.A., Kyle, R.A., Lacy, M.Q., Burritt, M.F., Therneau, T.M., Greipp, P.R., Witzig, T.E., Lust, J.A., Rajkumar, S.V., Fonseca, R., Zeldenrust, S.R., McGregor, C.G. & Jaffe, A.S. (2004) Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. Journal of Clinical Oncology, 22, 3751-3757.
5. Dispenzieri, A., Lacy, M.Q., Zeldenrust, S.R., Hayman, S.R., Kumar, S.K., Geyer, S.M., Lust, J.A., Allred, J.B., Witzig, T.E., Rajkumar, S.V., Greipp, P.R., Russell, S.J., Kabat, B. & Gertz, M.A. (2007) The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. Blood, 109, 465-470.
6. Dispenzieri, A., Buadi, F., Laumann, K., LaPlant, B., Hayman, S.R., Kumar, S.K., Dingli, D., Zeldenrust, S.R., Mikhael, J.R., Hall, R., Rajkumar, S.V., Reeder, C., Fonseca, R., Bergsagel, P.L., Stewart, A.K., Roy, V., Witzig, T.E., Lust, J.A., Russell, S.J., Gertz, M.A. & Lacy, M.Q. (2012) Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis. Blood, 119, 5397-5404.
7. Dubrey, S.W., Reece, D.E., Sanchorawala, V., Hegenbart, U., Merlini, G., Palladini, G., Fermand, J.P., Vescio, R.A., Bladé, J., Heffner, L.T., Hassoun, H., Liu, X., Enny, C., Ramaswami, P., Elsayed, Y., Van De Velde, H., Mortimer, S., Cakana, A. & Comenzo, R.L.; Velcade Can2007 Study Group. (2011) Bortezomib in a phase 1 trial for patients with relapsed AL amyloidosis: cardiac responses and overall effects. QJM: An International Journal of Medicine, 104, 957-970.
8. Gertz, M.A., Comenzo, R., Falk, R.H., Fermand, J.P., Hazenberg, B.P., Hawkins, P.N., Merlini, G., Moreau, P., Ronco, P., Sanchorawala, V., Sezer, O., Solomon, A. & Grateau, G. (2005) Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. American Journal of Hematology, 79, 319-328.
9. Gertz, M.A., Lacy, M.Q., Lust, J.A., Greipp, P.R., Witzig, T.E. & Kyle, R.A. (2008) Long-term risk of myelodysplasia in melphalan-treated patients with immunoglobulin light-chain amyloidosis. Haematologica, 93, 1402-1406.
10. Gertz, M.A., Lacy, M.Q., Dispenzieri, A., Hayman, S.R., Kumar, S.K., Dingli, D., Ansell, S.M., Gastineau, D.A., Inwards, D.J., Johnston, P.B., Litzow, M.R., Micallef, I.N., Porrata, L.F., Leung, N., Hogan, W.J. & Buadi, F.K. (2010) Autologous stem cell transplant for immunoglobulin light chain amyloidosis: a status report. Leukemia & Lymphoma, 51, 2181-2187.
11. Girnius, S., Seldin, D.C., Meier-Ewert, H.K., Sloan, J.M., Quillen, K., Ruberg, F.L., Berk, J.L., Doros, G. & Sanchorawala, V. (2014) Safety and efficacy of high-dose melphalan and auto-SCT in patients with AL amyloidosis and cardiac involvement. Bone Marrow Transplantation, 49, 434-439.
12. Jaccard, A., Moreau, P., Leblond, V., Leleu, X., Benboubker, L., Hermine, O., Recher, C., Asli, B., Lioure, B., Royer, B., Jardin, F., Bridoux, F., Grosbois, B., Jaubert, J., Piette, J.C., Ronco, P., Quet, F., Cogne, M., Fermand, J.P. & Myélome Autogreffe (MAG) and Intergroupe Francophome du Myélome (IFM) Intergroup. (2007) High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. New England Journal of Medicine, 357, 1083-1093.
13. Kaplan, G.L. & Meier, P. (1958) Non-parametric estimation from incomplete observations. Journal of the American Statistical Association, 53, 457-481.
14. Kastritis, E., Anagnostopoulos, A., Roussou, M., Toumanidis, S., Pamboukas, C., Migkou, M., Tassidou, A., Xilouri, I., Delibasi, S., Psimenou, E., Mellou, S., Terpos, E., Nanas, J. & Dimopoulos, M.A. (2007) Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone. Haematologica, 92, 1351-1358.
15. Kastritis, E., Wechalekar, A.D., Dimopoulos, M.A., Merlini, G., Hawkins, P.N., Perfetti, V., Gillmore, J.D. & Palladini, G. (2010) Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis. Journal of Clinical Oncology, 28, 1031-1037.
16. Kastritis, E., Terpos, E., Roussou, M., Gavriatopoulou, M., Pamboukas, C., Boletis, I., Marinaki, S., Apostolou, T., Nikitas, N., Gkortzolidis, G., Michalis, E., Delimpasi, S. & Dimopoulos, M.A. (2012) A phase 1/2 study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone (RdC) in AL amyloidosis. Blood, 119, 5384-5390.
17. Kumar, S.K., Hayman, S.R., Buadi, F.K., Roy, V., Lacy, M.Q., Gertz, M.A., Allred, J., Laumann, K.M., Bergsagel, L.P., Dingli, D., Mikhael, J.R., Reeder, C.B., Stewart, A.K., Zeldenrust, S.R., Greipp, P.R., Lust, J.A., Fonseca, R., Russell, S.J., Rajkumar, S.V. & Dispenzieri, A. (2012a) Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial. Blood, 119, 4860-4867.
18. Kumar, S., Dispenzieri, A., Lacy, M.Q., Hayman, S.R., Buadi, F.K., Colby, C., Laumann, K., Zeldenrust, S.R., Leung, N., Dingli, D., Greipp, P.R., Lust, J.A., Russell, S.J., Kyle, R.A., Rajkumar, S.V. & Gertz, M.A. (2012b) Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. Journal of Clinical Oncology, 30, 989-995.
19. Kyle, R.A., Linos, A., Beard, C.M., Linke, R.P., Gertz, M.A., O'Fallon, W.M. & Kurland, L.T. (1992) Incidence and natural history of primary systemic amiloidosis in Olmsted County, Minnesota, 1950 through 1989. Blood, 79, 1817-1822.
20. Lamm, W., Willenbacher, W., Lang, A., Zojer, N., Müldür, E., Ludwig, H., Schauer-Stalzer, B., Zielinski, C.C. & Drach, J. (2011) Efficacy of the combination of bortezomib and dexamethasone in systemic AL amyloidosis. Annals of Hematology, 90, 201-206.
21. Masson, S., Vago, T., Baldi, G., Salio, M., De Angelis, N., Nicolis, E., Maggioni, A.P., Latini, R., Norbiato, G. & Bevilacqua, M. (2002) Comparative measurement of N-terminal pro-brain natriuretic peptide and brain natriuretic peptide in ambulatory patients with heart failure. Clinical Chemistry and Laboratory Medicine, 40, 761-763.
22. Mikhael, J.R., Schuster, S.R., Jimenez-Zepeda, V.H., Bello, N., Spong, J., Reeder, C.B., Stewart, A.K., Bergsagel, P.L. & Fonseca, R. (2012) Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis. Blood, 119, 4391-4394.
23. Moreau, P., Jaccard, A., Benboubker, L., Royer, B., Leleu, X., Bridoux, F., Salles, G., Leblond, V., Roussel, M., Alakl, M., Hermine, O., Planche, L., Harousseau, J.L. & Fermand, J.P. (2010) Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1/2 dose-escalation study. Blood, 116, 4777-4782.
24. Palladini, G., Russo, P., Nuvolone, M., Lavatelli, F., Perfetti, V., Obici, L. & Merlini, G. (2007) Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis. Blood, 110, 787-788.
25. Palladini, G., Dispenzieri, A., Gertz, M.A., Kumar, S., Wechalekar, A., Hawkins, P.N., Schönland, S., Hegenbart, U., Comenzo, R., Kastritis, E., Dimopoulos, M.A., Jaccard, A., Klersy, C. & Merlini, G. (2012) New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. Journal of Clinical Oncology, 30, 4541-4549.
26. Palladini, G., Milani, P., Rosin, M.V., Foli, A. & Merlini, G. (2013a) High-dose pomalidomide and dexamethasone induce rapid responses in patients with AL amyloidosis exposed to alkylators, immune modulatory drugs, and proteasome inhibitors. Blood (ASH Annual Meeting Abstracts), 122, 288.
27. Palladini, G., Russo, P., Milani, P., Foli, A., Lavatelli, F., Nuvolone, M., Perlini, S. & Merlini, G. (2013b) A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis. Haematologica, 98, 433-436.
28. Palladini, G., Milani, P., Foli, A., Obici, L., Lavatelli, F., Nuvolone, M., Caccialanza, R., Perlini, S. & Merlini, G. (2014) Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach. Haematologica, 99, 743-750.
29. Reece, D.E., Hegenbart, U., Sanchorawala, V., Merlini, G., Palladini, G., Bladé, J., Fermand, J.P., Hassoun, H., Heffner, L., Vescio, R.A., Liu, K., Enny, C., Esseltine, D.L., van de Velde, H., Cakana, A. & Comenzo, R.L. (2011) Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study. Blood, 118, 865-873.
30. Sanchorawala, V., Wright, D.G., Rosenzweig, M., Finn, K.T., Fennessey, S., Zeldis, J.B., Skinner, M. & Seldin, D.C. (2007) Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial. Blood, 109, 492-496.
31. Sanchorawala, V., Finn, K.T., Fennessey, S., Shelton, A., Doros, G., Zeldis, J.B. & Seldin, D.C. (2010) Durable hematologic complete responses can be achieved with lenalidomide in AL amyloidosis. Blood, 116, 1990-1991.
32. Sanchorawala, V., Patel, J.M., Sloan, J.M., Shelton, A.C., Zeldis, J.B. & Seldin, D.C. (2013) Melphalan, lenalidomide and dexamethasone for the treatment of immunoglobulin light chain amyloidosis: results of a phase II trial. Haematologica, 98, 789-792.
33. Skinner, M., Sanchorawala, V., Seldin, D.C., Dember, L.M., Falk, R.H., Berk, J.L., Anderson, J.J., O'Hara, C., Finn, K.T., Libbey, C.A., Wiesman, J., Quillen, K., Swan, N. & Wright, D.G. (2004) High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Annals of Internal Medicine, 140, 85-93.
34. Venner, C.P., Lane, T., Foard, D., Rannigan, L., Gibbs, S.D., Pinney, J.H., Whelan, C.J., Lachmann, H.J., Gillmore, J.D., Hawkins, P.N. & Wechalekar, A.D. (2012) Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival. Blood, 119, 4387-4390.